AbbVie Inc (ABBV)vsAveanna Healthcare Holdings Inc (AVAH)
ABBV
AbbVie Inc
$253.35
+4.20%
HEALTHCARE · Cap: $447.62B
AVAH
Aveanna Healthcare Holdings Inc
$8.48
+0.75%
HEALTHCARE · Cap: $1.84B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2391% more annual revenue ($62.82B vs $2.52B). AVAH leads profitability with a 10.4% profit margin vs 5.8%. AVAH trades at a lower P/E of 7.0x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AVAH
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$253.35
$107.13 premium
Margin of Safety
-84.3%
Fair Value
$4.33
Current Price
$8.48
$4.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Earnings expanding 612.0% YoY
15.9% revenue growth
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : AVAH
The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : AVAH
The primary concerns for AVAH are Market Cap, Free Cash Flow, Altman Z-Score. Debt-to-equity of 6.26 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while AVAH is a growth play — different risk/reward profiles.
AVAH carries more volatility with a beta of 1.93 — expect wider price swings.
AVAH is growing revenue faster at 15.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 62/100) and 12.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Aveanna Healthcare Holdings Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?